Royalty Pharma (NASDAQ: RPRX) will report Q3 2026 earnings pre-market on Nov. 4. After pulling back in September due to a major setback with one of its drug candidates, the pharmaceutical royalty holding company's shares have been soaring back toward their 52-week high. Yet while this may tempt you to speculate on a post-earnings rally, remember to keep the long term in mind with this stock. Earnings day may not necessarily catalyze share price action, but there's still reason to remain bullish on Royalty's long-term prospects. Image source: Getty Images.
CryptoAlerta — análise de criptomoedas e mercado em tempo real